Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- AstraZeneca to Simultaneously Start All PI Trials Worldwide
December 25, 2006
- SMO Group Holds CRC Training Seminar
December 25, 2006
- Sanofi-aventis to Start Large Epidemiological Study in Cerebral Infarction Patients
December 25, 2006
- Pazufloxacin Can Now Be Used as 1st-Choice Drug: Toyama, MPC
December 25, 2006
- Wyeth, Kyushu Univ. Moving Forward with Their R&D Alliance
December 25, 2006
- Chugai to Copromote Otsuka's Antiplatelet Agent Pletaal
December 25, 2006
- REGULATORY NEWS IN BRIEF
December 25, 2006
- Pfizer to Continue Launching Series of New Drugs: President Iwasaki
December 25, 2006
- PMDA to Increase Transparency on Posting of Ex-Employees of Companies
December 25, 2006
- BUSINESS NEWS IN BRIEF
December 25, 2006
- Nippon Keidanren Leaders Exchange Opinions with Korosho Leaders
December 25, 2006
- Novartis Highlights Strong R&D Pipeline
December 25, 2006
- Korosho Hears from 5 Parties to Promptly Bring New Drugs to Patients
December 25, 2006
- R&D NEWS IN BRIEF
December 25, 2006
- System That Fairly Awards Innovation Needed: WG for New Industry Vision
December 25, 2006
- Risk Classification for OTC Drugs Nearly Complete: PFSB
December 25, 2006
- Transfer Price Taxation System to Be Revised in FY2007
December 25, 2006
- Asahi Kasei Medical, Kuraray Medical to Integrate Businesses
December 25, 2006
- Tie-ups of Hansha Spreading to Kanto, Shikoku: Mr Eguchi
December 25, 2006
- MEDICAL DEVICE NEWS IN BRIEF
December 25, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…